Abiopharma

Form 7 Monthly Progress Report August 2025

Longer-Term Follow-Up of Western Patients Showed Improving, Favorable Trend in Overall Survival in Global Phase III HARMONi Clinical Trial for Ivonescimab Plus Chemotherapy in 2L+ EGFRm NSCLC

Johnson & Johnson - Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plusLAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

Data published in The New England Journal of Medicine demonstrate RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) is re-setting survival expectations in first-line EGFR-mutated lung cancer

Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years

Best Budget Student Laptops for Academic Success in 2025

Best Business Office Monitors for Professional Workspaces in 2025

Best Business Laptops for Professional Productivity in 2025

Best Closed Back Headphones for Audio Isolation and Quality (2025)

Under Desk Treadmills: Top Models and Buying Guide

ALT Investors Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit

Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism

Johnson & Johnson - RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) prevents acquired resistance versus osimertinib in first-line EGFR-mutated non-small cell lung cancer

Garden Stage Limited - Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency